U.S. Tech Hardware Stock News

NasdaqGS:HOOD
NasdaqGS:HOODCapital Markets

A Look At Robinhood Markets (HOOD) Valuation As It Expands With Platinum Card And Tokenized Stocks

Robinhood Markets (HOOD) is drawing fresh attention after launching a high-fee Platinum credit card and rolling out tokenized stocks for European customers. These moves extend its reach beyond traditional trading into payments and crypto infrastructure. See our latest analysis for Robinhood Markets. Despite the new Platinum card and tokenized stocks grabbing headlines, Robinhood’s recent 1-day share price return of 2.62% comes after a tougher stretch, with a 90-day share price return decline...
NasdaqGS:CYTK
NasdaqGS:CYTKBiotechs

Cytokinetics MYQORZO Data Sheds Light On oHCM Outlook And Valuation

Cytokinetics (NasdaqGS:CYTK) presented new clinical data on MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy at a major cardiology conference. The updates covered exercise capacity outcomes, effectiveness across patients with and without hypertension, and safety during treatment interruption and restart. The new analyses expand the clinical profile of MYQORZO, a recently approved oHCM therapy, and add detail on how the drug performs in real treatment scenarios. Cytokinetics...
NYSE:SFBS
NYSE:SFBSBanks

Is ServisFirst Bancshares (SFBS) Offering A Chance After Recent Share Price Weakness

Wondering whether ServisFirst Bancshares is attractively priced at its current level? This article focuses squarely on what the recent share performance might be telling you about value. The stock last closed at US$73.73, with returns of 2.7% year to date, a 14.4% decline over the past month, and a 9.7% decline over the past year, while still showing a 35.2% gain over three years and 31.1% over five years. These mixed returns have kept ServisFirst Bancshares on the radar for investors who...
NasdaqGS:DOCU
NasdaqGS:DOCUSoftware

Is DocuSign (DOCU) Offering Value After Recent Share Price Weakness?

Wondering whether DocuSign at around US$46.82 still lines up with what you would consider a fair price? This article walks through the key valuation checks so you can put the current share price in context. The stock has seen a mixed run recently, with a 3.8% decline over the last 7 days, a 4.5% gain over the last 30 days, and year to date and 1 year returns of 27.8% and 43.9% declines respectively. Recent headlines have continued to focus on DocuSign's role in digital agreement workflows...
NasdaqGS:HALO
NasdaqGS:HALOBiotechs

Could Halozyme (HALO) Returning David Ramsay as Interim CFO Reframe Its ENHANZE Royalty Story?

Halozyme Therapeutics has appointed David Ramsay as interim Chief Financial Officer, effective March 23, 2026, tasking him with overseeing all financial operations while the company continues its search for a permanent CFO. Ramsay’s return, after previously guiding Halozyme from a private business to a billion-dollar public biopharmaceutical company, offers investors continuity in financial leadership during a key transition period. We’ll now examine how Ramsay’s return as interim CFO may...
NYSE:ETSY
NYSE:ETSYMultiline Retail

How Investors Are Reacting To Etsy (ETSY) Refocusing On Reviews And Core Marketplace Operations

Earlier this month, PrintKK announced its integration with Etsy, allowing marketplace sellers to design and sell over 1,000 customizable products globally while PrintKK manages production, packaging, and shipping through its fulfillment network. Around the same time, Etsy overhauled its shop review system to use lifetime reviews with recency weighting and completed the sale of Depop, moves that sharpen focus on marketplace quality and core operations. Next, we’ll examine how Etsy’s shift to...
NYSE:CRM
NYSE:CRMSoftware

A Look At Salesforce (CRM) Valuation As Shares Rebound And AI Potential Is Reassessed

Salesforce stock in focus Salesforce (CRM) is drawing attention after recent share price moves, with the stock last closing at US$198.34. Investors are weighing this level against the company’s current earnings profile and customer relationship management focus. See our latest analysis for Salesforce. The recent 1 day share price return of 2.86% comes after a 90 day share price return of 22.19% and a 1 year total shareholder return decline of 28.89%. This indicates that short term momentum is...
NYSE:GOLD
NYSE:GOLDRetail Distributors

Gold.com Board Shift Brings New Capital Markets Focus For Investors

Gold.com (NYSE:GOLD) has appointed Juan Sartori to its Board of Directors with immediate effect. The move coincides with the retirement of longtime director Beverley Lepine after more than a decade of service. Sartori brings experience in digital finance, commodities, and global capital markets to the company’s board. Gold.com, trading at $46.72, has seen a 34.4% return year to date and a 72.0% return over the past year, with longer term 3 year and 5 year returns of 74.1% and 183.2%...
NasdaqGS:SBUX
NasdaqGS:SBUXHospitality

Assessing Starbucks (SBUX) Valuation After Mixed Share Performance And Slower International Growth Concerns

Recent performance snapshot and why Starbucks is on investors’ radar Starbucks (SBUX) has drawn fresh attention after a mixed run in the stock, with a 1.3% decline over the past day and a 2.0% dip over the past week, contrasting with gains over the past month and past 3 months. Against that backdrop, the company’s latest reported annual figures show revenue of US$37.7b and net income of US$1.4b, with year on year revenue growth of 4.4% and net income growth of 29.1%. See our latest analysis...
NYSE:MSI
NYSE:MSICommunications

A Look At Motorola Solutions (MSI) Valuation After Peter Leav’s Board Appointment And Exacom Acquisition

Motorola Solutions (MSI) is back on investors’ radar after the board expanded to add software and cybersecurity veteran Peter Leav, along with the recent Exacom acquisition that deepens its focus on mission-critical public safety technology. See our latest analysis for Motorola Solutions. The recent 2.8% 7 day share price return and 1.9% 30 day share price return have come alongside the Exacom deal and Peter Leav’s board appointment. A 29.4% 90 day share price return and 12.6% 1 year total...
NYSE:LYB
NYSE:LYBChemicals

Will LyondellBasell (LYB) Recast Its Low‑Carbon Story Under New Investor Relations Leadership?

LyondellBasell recently announced that David Dennison, a nearly 30‑year industry veteran who joined the company in 2007 and most recently served as a vice president in its Circular and Low Carbon Solutions business, will become head of investor relations in May 2026, succeeding retiring long‑time executive Dave Kinney. Dennison’s background in planning, commercial leadership and circular solutions could meaningfully shape how LyondellBasell communicates its transition toward recycling,...
NasdaqGS:AVPT
NasdaqGS:AVPTSoftware

How Investors May Respond To AvePoint (AVPT) Launching AgentPulse For Multicloud AI Agent Governance

In early March 2026, AvePoint announced the past general availability of its AgentPulse Command Center, expanding multicloud observability and governance for autonomous AI agents across Microsoft 365 and Google Cloud, with unified monitoring, lifecycle management, and cost controls to reduce shadow AI, data exposure, and surprise usage bills. A distinctive feature is the single-pane view across Copilot Studio, Microsoft Foundry, SharePoint agents, and Vertex AI, giving enterprises...
NYSE:LYV
NYSE:LYVEntertainment

Why Live Nation (LYV) Is Down 5.3% After DOJ Antitrust Settlement And Extended Oversight

Live Nation Entertainment has settled the US Department of Justice’s antitrust lawsuit without admitting wrongdoing, extending its consent decree by eight years and setting up a US$280 million fund to address state damages claims. The agreement lets Live Nation retain Ticketmaster under stricter operating conditions while leaked internal messages and ongoing state actions keep its ticketing practices under intense scrutiny. We’ll now examine how the extended DOJ consent decree and continuing...
NasdaqGS:INCY
NasdaqGS:INCYBiotechs

How Diverging Zynyz Outcomes In Cancer Trials At Incyte (INCY) Have Changed Its Investment Story

In early March 2026, Incyte reported a U.S. FDA Complete Response Letter for an additional lung cancer indication of Zynyz due to compliance issues at a third‑party fill‑finish facility, while also securing European Commission approval for Zynyz in combination with chemotherapy as a first‑line treatment for advanced anal cancer. The contrast between a regulatory setback tied to a partner’s manufacturing site in the U.S. and a fresh approval expanding Zynyz’s reach in Europe underscores how...
NasdaqGS:FTDR
NasdaqGS:FTDRConsumer Services

Frontdoor (FTDR) Valuation Check After Strong Q4 Beat And Softer Full Year Guidance

Frontdoor (FTDR) is back in focus after reporting Q4 revenue of $433 million, a 13.1% year over year increase, along with earnings that exceeded expectations and full year revenue guidance slightly below projections. See our latest analysis for Frontdoor. Since the earnings release, Frontdoor’s share price has moved to US$64.22, with a 13.38% 1 month share price return and a 69.58% 1 year total shareholder return, which may suggest building momentum despite some recent short term pullback. If...
NYSE:LEU
NYSE:LEUOil and Gas

Centrus Energy (LEU) Is Up 8.7% After Oklo JV, AI Push Reframe Nuclear Fuel Role – What’s Changed

In March 2026, Oklo Inc. and Centrus Energy agreed to pursue a joint venture for high-assay low-enriched uranium deconversion at Centrus’ Piketon, Ohio site, while Centrus also reported lower-than-expected quarterly earnings affected by a delayed Russian shipment and outlined increased capital spending plans. Centrus’ recent collaboration with Palantir on AI-driven enrichment optimization and its talks with Oklo on an integrated HALEU hub highlight how technology and fuel-cycle partnerships...
NasdaqGS:UBSI
NasdaqGS:UBSIBanks

Is United Bankshares (UBSI) Still Sensibly Priced After The Recent Share Price Pullback?

Wondering if United Bankshares at around US$39.38 is still a fair deal or starting to look stretched? This article breaks down what the current share price might be implying about value. The stock’s returns range from a 1.4% decline over the last 7 days and a 10.7% decline over the last 30 days, to gains of 2.6% year to date, 17.5% over 1 year, 25.7% over 3 years and 25.2% over 5 years. These figures can mean very different things depending on how you think about risk and timing. Recent...
NasdaqGS:NBIS
NasdaqGS:NBISSoftware

Nebius Meta Deal Secures Major AI Cloud Revenue Visibility And Questions

Nebius Group (NasdaqGS:NBIS) has signed a multi year AI infrastructure supply agreement with Meta Platforms valued at $27b. The deal spans five years and involves providing dedicated GPU capacity using NVIDIA's Vera Rubin platform across multiple global sites. The contract is described as one of the largest AI cloud agreements signed to date and secures Nebius a meaningful share of Meta's planned AI infrastructure spend. Nebius Group comes into this agreement with strong recent share price...
NasdaqGS:ORLY
NasdaqGS:ORLYSpecialty Retail

O'Reilly Automotive Debt Issuance Raises Questions On Long Term Flexibility

O'Reilly Automotive completed a significant fixed income offering of senior unsecured notes due in 2036. The transaction adds long dated debt to the company’s balance sheet, which may affect its capital structure and liquidity profile. The terms of the notes and investor demand can offer clues about how credit markets currently view O'Reilly Automotive, ticker NasdaqGS:ORLY. Investors watching NasdaqGS:ORLY now have a fresh data point to consider alongside the current share price of $90.46...
NasdaqGS:XRAY
NasdaqGS:XRAYMedical Equipment

Is Dentsply Sirona's (XRAY) Dental‑Dedicated MRI Bet Quietly Redefining Its Competitive Moat?

Dentsply Sirona and Siemens Healthineers recently received US FDA clearance for the MAGNETOM Free.Max Dental Edition, the first dental‑dedicated MRI system clinically validated for multiple specialties including endodontics, periodontics, TMJ, orthodontics, and tooth extraction. This non‑ionizing, dental‑specific MRI platform, with a focused field of view and sub‑20‑minute workflow, could meaningfully enhance complex diagnostic capabilities in hospitals, large clinics, and academic...
NasdaqGS:GLUE
NasdaqGS:GLUEBiotechs

Does Monte Rosa (GLUE)–J&J ERLEADA Supply Deal Reframe GLUE’s MYC Degrader Investment Story?

Monte Rosa Therapeutics announced a past supply agreement with Johnson & Johnson under which Johnson & Johnson will provide ERLEADA (apalutamide) for a Monte Rosa–sponsored Phase 2 trial evaluating MRT-2359 in patients with metastatic castration-resistant prostate cancer (mCRPC) with androgen receptor mutations, with study initiation planned for the third quarter of 2026. This collaboration builds on encouraging early clinical data for MRT-2359 plus enzalutamide and highlights growing...
NYSE:GS
NYSE:GSCapital Markets

Lakshmi Mittal Retirement Signals Planned Board Refresh At Goldman Sachs

Lakshmi Mittal plans to retire from the Goldman Sachs Group (NYSE:GS) Board of Directors at the 2026 Annual Meeting. The decision follows the company’s age-based retirement policy, as confirmed by a recent board action. Goldman Sachs Group, traded as NYSE:GS, operates as a global investment banking, securities, and asset management firm. Board composition is an important part of how a company like this oversees risk, capital allocation, and long term business priorities. Mittal’s planned...
NasdaqGM:TLS
NasdaqGM:TLSSoftware

Telos (TLS) Q4 Loss Rebound Challenges Bullish Margin Improvement Narratives

Telos (TLS) just closed out FY 2025 with Q4 revenue of US$46.8 million and a basic EPS loss of US$0.22, capping a year in which trailing twelve month revenue came in at US$164.8 million and EPS on the same basis was a loss of US$0.50. Over recent quarters the company has seen revenue move from US$26.4 million in Q4 2024 to US$30.6 million in Q1 2025, US$36.0 million in Q2, US$51.4 million in Q3, and US$46.8 million in Q4, while quarterly basic EPS losses ranged between US$0.03 and US$0.22...
NYSE:GPGI
NYSE:GPGITech

GPGI (GPGI) Is Down 18.5% After Revenue Collapse And Rising Losses Reveal Shifting Investment Narrative

GPGI, Inc. recently reported full-year 2025 results showing sales of US$59.82 million versus US$420.57 million a year earlier, with its net loss widening to US$136.01 million, and shortly after, Executive Chairman Dave Cote presented at the JPMorgan Industrials Conference 2026 in Washington, D.C. Together with the appointment of experienced capital-markets lawyer David A.P. Marshall as Chief Legal Counsel and Corporate Secretary, these developments give investors fresh insight into GPGI’s...